EP1210110A4 - Prion protein binding proteins and uses thereof - Google Patents

Prion protein binding proteins and uses thereof

Info

Publication number
EP1210110A4
EP1210110A4 EP00943291A EP00943291A EP1210110A4 EP 1210110 A4 EP1210110 A4 EP 1210110A4 EP 00943291 A EP00943291 A EP 00943291A EP 00943291 A EP00943291 A EP 00943291A EP 1210110 A4 EP1210110 A4 EP 1210110A4
Authority
EP
European Patent Office
Prior art keywords
binding proteins
protein binding
prion protein
prion
proteins
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00943291A
Other languages
German (de)
French (fr)
Other versions
EP1210110A1 (en
Inventor
Neil R Cashman
Vincent Dodelet
Eustache Paramithiotis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
McGill University
Thallion Pharmaceuticals Inc
Original Assignee
McGill University
Caprion Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by McGill University, Caprion Pharmaceuticals Inc filed Critical McGill University
Publication of EP1210110A1 publication Critical patent/EP1210110A1/en
Publication of EP1210110A4 publication Critical patent/EP1210110A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/20—Screening for compounds of potential therapeutic value cell-free systems
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2828—Prion diseases
EP00943291A 1999-06-29 2000-06-29 Prion protein binding proteins and uses thereof Withdrawn EP1210110A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US34242699A 1999-06-29 1999-06-29
US342426 1999-06-29
PCT/US2000/017927 WO2001000235A1 (en) 1999-06-29 2000-06-29 Prion protein binding proteins and uses thereof

Publications (2)

Publication Number Publication Date
EP1210110A1 EP1210110A1 (en) 2002-06-05
EP1210110A4 true EP1210110A4 (en) 2003-03-19

Family

ID=23341775

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00943291A Withdrawn EP1210110A4 (en) 1999-06-29 2000-06-29 Prion protein binding proteins and uses thereof

Country Status (5)

Country Link
EP (1) EP1210110A4 (en)
JP (1) JP2003531356A (en)
AU (1) AU5778400A (en)
CA (1) CA2376914A1 (en)
WO (1) WO2001000235A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7041807B1 (en) 1999-06-23 2006-05-09 Caprion Pharmaceuticals, Inc. Antibodies to a YYX epitope of a mammalian prion protein
AU6408901A (en) * 2000-07-07 2002-01-21 Applied Research Systems Early diagnosis of conformational diseases
CA2812761C (en) 2001-10-05 2018-03-20 Steris Inc. In vitro model for priocidal activity
US20040072236A1 (en) * 2002-09-27 2004-04-15 Neil Cashman PrPSc -interacting molecules and uses thereof
NZ572892A (en) * 2002-12-03 2010-03-26 Univ North Carolina State Prion protein ligands with the sequence YVHEA
US20050054003A1 (en) * 2003-09-10 2005-03-10 Stenland Christopher J. Prion clearance using particulate metal oxides
EP1571449A1 (en) * 2004-03-01 2005-09-07 Stichting Sanquin Bloedvoorziening Prion immunoassay and separation method
GB0519198D0 (en) * 2005-09-20 2005-10-26 Univ Cambridge Tech Tse detection
EP2407555A1 (en) 2010-07-14 2012-01-18 Fundació Institut de Recerca Hospital Universitari Vall d'Hebron, Fundació Privada Methods and kits for the diagnosis of prostate cancer
EP2407554A1 (en) 2010-07-14 2012-01-18 Fundacio Institut de Recerca de l'Hospital Universitari Vall d'Hebron Methods and kits for the diagnosis of prostate cancer

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993023432A1 (en) * 1992-05-15 1993-11-25 New York University Soluble prion polypeptides, and methods for detecting and purifying thereof
EP1186662A2 (en) * 1996-05-29 2002-03-13 McGILL UNIVERSITY Prion binding proteins and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4806627A (en) * 1987-05-29 1989-02-21 Research Foundation Of Mental Hygiene Inc. Hybrid cell lines producing monoclonal antibodies dircted against scrapie-associated fibril proteins
US5679530A (en) * 1995-04-12 1997-10-21 Ludwig Institute For Cancer Research Isolated protein having molecular weight of from about 55 kilodaltons to about 65 kilodaltons (SDS-page) which binds to prion protein
US5750361A (en) * 1995-11-02 1998-05-12 The Regents Of The University Of California Formation and use of prion protein (PRP) complexes
DE69714451T2 (en) * 1996-05-29 2003-01-30 Univ Montreal Mcgill PRION-BINDING PROTEINS AND THEIR USE

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993023432A1 (en) * 1992-05-15 1993-11-25 New York University Soluble prion polypeptides, and methods for detecting and purifying thereof
EP1186662A2 (en) * 1996-05-29 2002-03-13 McGILL UNIVERSITY Prion binding proteins and uses thereof

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
BROWN DAVID R ET AL: "The cellular prion protein binds copper in vivo.", NATURE (LONDON), vol. 390, no. 6661, 18 December 1997 (1997-12-18), pages 684 - 687, XP002206825, ISSN: 0028-0836 *
FORLONI G ET AL: "Neurotoxicity of a prion protein fragment.", NATURE. ENGLAND 8 APR 1993, vol. 362, no. 6420, 8 April 1993 (1993-04-08), pages 543 - 546, XP000941706, ISSN: 0028-0836 *
HOFFMANN INES ET AL: "Cloning and Expression Analysis of a Novel Mesodermally Expressed Cadherin.", DEVELOPMENTAL BIOLOGY, vol. 169, no. 1, 1995, pages 337 - 346, XP000576704, ISSN: 0012-1606 *
KURSCHNER C ET AL: "ANALYSIS OF INTERACTION SITES IN HOMO- AND HETEROMERIC COMPLEXES CONTAINING BCL-2 FAMILY MEMBERS AND THE CELLULAR PRION PROTEIN", MOLECULAR BRAIN RESEARCH, ELSEVIER SCIENCE BV, AMSTERDAM, NL, vol. 37, no. 1/2, 1996, pages 249 - 258, XP002056075, ISSN: 0169-328X *
RIEGER R ETAL: "The human 37-kDa laminin receptor precursor interacts with the prion protein in eukaryotic cells", NATURE MEDICINE, NATURE PUBLISHING, CO, US, vol. 3, no. 12, 1 December 1997 (1997-12-01), pages 1383 - 1388, XP002094757, ISSN: 1078-8956 *
See also references of WO0100235A1 *
SUGIMOTO KEISHI ET AL: "Molecular cloning and characterization of a newly identified member of the cadherin family, PB-cadherin.", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 271, no. 19, 1996, pages 11548 - 11556, XP002206824, ISSN: 0021-9258 *

Also Published As

Publication number Publication date
AU5778400A (en) 2001-01-31
EP1210110A1 (en) 2002-06-05
WO2001000235A1 (en) 2001-01-04
JP2003531356A (en) 2003-10-21
CA2376914A1 (en) 2001-01-04

Similar Documents

Publication Publication Date Title
IL125463A0 (en) Interleukin-18 binding proteins their preparation and use
AU5091199A (en) Prion protein and uses thereof
GB9921125D0 (en) Proteins
AU7829700A (en) Protein phosphatase and kinase proteins
EP1210110A4 (en) Prion protein binding proteins and uses thereof
EP1186615A4 (en) Novel protein and dna thereof
GB9928950D0 (en) Binding protein
GB9918155D0 (en) Proteins and peptides
EP1189938A4 (en) Secreted proteins and uses thereof
AU2136401A (en) P450rai-2 and related proteins
EP1080185A4 (en) Myelin basic protein peptides and uses thereof
EP1179000A4 (en) Secreted proteins and uses thereof
AU5495500A (en) Decorin binding protein essential peptides and methods of use
AU1320600A (en) Human rna binding proteins
EP1044212A4 (en) Human fk506 binding proteins
EP1142999A4 (en) Novel protein and dna thereof
AU2001276899A1 (en) Mammalian mdm2 binding proteins and uses thereof
AU6894398A (en) Human gtp binding protein
EP1159413A4 (en) Secreted proteins and uses thereof
EP1127066A4 (en) Modified proteins
EP1111047A4 (en) Novel protein and dna thereof
AU2001256454A1 (en) Prion proteins and their uses
PL350339A1 (en) Novel proteins and uses thereof
GB9726956D0 (en) Protein binding polypeptides
HK1093750A1 (en) Binding molecules for human factor viii and factor viii-like proteins

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20020129

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

A4 Supplementary search report drawn up and despatched

Effective date: 20030131

17Q First examination report despatched

Effective date: 20030512

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: MCGILL UNIVERSITY

Owner name: CAPRION PHARMACEUTICALS, INC.

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20030923